Not Yet RecruitingPhase 2

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

31 participantsStarted 2026-06-01

Plain-language summary

This is a single-arm, single-center, exploratory study aimed at exploring the treatment of RAS wild-type recurrent/metastatic colorectal cancer with the combination of becotatug vedotin and cetuximab as a salvage therapy

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Volunteer to sign the informed consent form, fully understand and sign the informed consent (ICF) for this study willing to follow and capable of completing all trial procedures
✓. No gender restriction, aged ≥18 years (as of the day of signing the informed consent form)
✓. Histologically or cytologically confirmed metastatic RAS wild-type colorectal cancer
✓. Patients should have received the following treatments:

Exclusion criteria

✕. Presence of ≥ Grade 2 peripheral neuropathy (based on CTCAE 5.0)
✕. Expected to require surgery or any other form of systemic or local anti-tumor treatment during the study period
✕. Having undergone any of the following treatments: 1) Previously receiving antibody-conjugated drugs loaded with methotrexate

What they're measuring

ORR

Timeframe: From enrollment to the end of treatmen at 1 year

Trial details

NCT IDNCT07490119

SponsorFudan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-06-01

Contact for this trial

LU WANG

+86 18121299555 cms024mm@163.com

View on ClinicalTrials.gov More RAS Wild Type mCRC trials